# A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.

> **NCT00199836** · PHASE1 · COMPLETED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 14 (actual)

## Conditions studied

- Cancer
- Neoplasm

## Interventions

- **BIOLOGICAL:** NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51

## Key facts

- **NCT ID:** NCT00199836
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09-03
- **Primary completion:** 2005-09-05
- **Final completion:** 2006-06-06
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2022-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00199836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00199836, "A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00199836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*